Since the introduction of radioiodinated metaiodobenzylguanidine in 1980, considerable
research has been performed, both in the chemical field and in medical sciences. However …

INTRODUCTION: Neuroblastoma is the most common pediatric extracranial solid cancer.
This tumor is characterized by metaiodobenzylguanidine (MIBG) avidity in 90% of cases …

Treatment with 131I-metaiodobenzylguanidine (MIBG) has been introduced to the
management of neuroendocrine tumors (NET) nearly 30 years ago. It provides efficient …

Incomplete response to therapy may compromise the outcome of children with advanced
neuroblastoma. In an attempt to improve tumour response we incorporated 131 I …

Disseminated neuroblastoma after infancy has a prognosis of approximately 10–20% with
conventional therapy. We investigated the role of high-dose chemotherapy (HDCT) with …

Aim: 131 I-meta-iodobenzylguanidine (131 I-MIBG) therapy has been used in
neuroblastoma treatment for many years but its value in high intensive first line treatment …

Abstract From 1984 to 1989, 47 children with relapsed, refractory, and/or metastasized
neuroblastoma were treated with 131l‐metaiodobenzylguanidine (mlBG) in several different …

Purpose Radiation dosimetry is a basic requirement for targeted radionuclide therapies
(TRT) which have become of increasing interest in nuclear medicine. Despite the significant …

Radioiodinated meta‐iodobenzylguanidine (MIBG) is increasingly used for the diagnosis
and targeted radiotherapy of neuro‐adrenergic tumors. We have investigated various …

Abstract Meta‐[211At] astatobenzylguanidine ([211At] MABG) is an astatinated analogue of
meta‐iodobenzylguanidine (MIBG) that could be of value for therapeutic applications. The …